

Gender: Male | Birth year: 1950 | WHO: 0

Tumor: Lung - Adenocarcinoma | Lesions: Liver | Stage: IV

Summary

Clinical summary

Relevant systemic treatment history	1/2023-9/2024	Osimertinib
Relevant other oncological history	None	
Previous primary tumor	None	
Relevant non-oncological history	2022	Rheumatoid arthritis

Recent molecular results

Hartwig WGS (20-Aug-2024)

Biopsy location	Liver (purity 50%)
Molecular tissue of origin prediction	Lung: Non-small cell (98%)
Tumor mutational load / burden	TML low (40) / TMB low (2)
Microsatellite (in)stability	Stable
HR status	Proficient (0)
High driver mutations	EGFR L858R, EGFR C797S, KRAS G12D
Amplified genes	None
Deleted genes	TP53
Homozygously disrupted genes	None
Gene fusions	None
Virus detection	None
Potentially actionable events with medium/low driver:	None

IHC results

PD-L1: Score 1%

Example trials that are open and considered eligible and currently have slots available (2 cohorts from 2 trials)

Trial	Cohort	Molecular	Warnings
METC 04 TEDR1	Lung cancer C797S cohort	EGFR C797S	None
METC 02 KAYRAS	Dose expansion - monotherapy - NSCLC	KRAS G12D	Variant(s) KRAS G12D in KRAS but subclonal likelihood of > 50%

Example trials that are open and considered eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		Hemoglobin 5.6 mmol/L below min of 6.0 mmol/L, History of rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining

Trial Matching Summary

Example trials and cohorts that may be eligible, but are closed (1)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose expansion - monotherapy		Hemoglobin 5.6 mmol/L below min of 6.0 mmol/L, History of rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining

Example trials and cohorts that are considered ineligible (2)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	Dose expansion - monotherapy - Colorectum	KRAS G12D	Tumor type
METC 03 NO-SEE797ES	Dose escalation - monotherapy		C797S detected in EGFR

Trial Matching Details

Potentially eligible open trials & cohorts

METC 01

Potentially eligible	Yes
Acronym	IEMOEN
Title	Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors

Rule	Reference	Evaluation
E-02	Has hemoglobin below 6 mmol/l	FAIL (potentially recoverable) Hemoglobin 5.6 mmol/L is below minimum of 6.0 mmol/L
I-03	Patient should have exhausted applicable available standard-of-care treatments.	WARN Patient has not exhausted SOC (at least platinum doublet remaining)
E-01	Has an active autoimmune disease that requires systemic treatment and poses a risk according to the investigator.	WARN Patient has history of condition(s) rheumatoid arthritis, which is indicative of autoimmune disease
E-03	Has absolute neutrophil count below 1.5 x 10^9/l	UNDETERMINED No measurement found for absolute neutrophil count
I-01	Patients must be ≥18 years old.	PASS Patient is at least 18 years old
I-02	IEMOEN monotherapy is indicated for the treatment of adults with advanced/metastatic solid tumors.	PASS Patient has solid primary tumor Tumor stage IV is considered metastatic

METC 01 - Dose escalation - monotherapy

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	Yes
Has slots available?	No

METC 01 - Dose expansion - monotherapy

Cohort ID	B
Potentially eligible?	Yes
Open for inclusion?	No
Has slots available?	No

METC 02

Potentially eligible	Yes
Acronym	KAYRAS
Title	A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer

Rule	Reference	Evaluation
I-04	Patient has confirmed KRAS G12D mutation	WARN Variant(s) KRAS G12D in KRAS detected in canonical transcript but subclonal likelihood of > 50%
I-03	ALAT and ASAT should be at most 3*ULN, or at most 5*ULN in case of liver metastases.	UNDETERMINED No measurement found for ASAT
I-01	Patient is ≥18 years old.	PASS Patient is at least 18 years old
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	PASS Tumor stage IV is considered metastatic

METC 02 - Dose expansion - monotherapy - NSCLC

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	PASS Patient has lung non-small cell carcinoma

METC 02 - Dose expansion - monotherapy - Colorectum

Cohort ID	B
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	FAIL Patient has no colorectal cancer

METC 04

Potentially eligible	Yes
Acronym	TEDR1
Title	TEDR1 Trial: A phase II trial to evaluate efficacy of specific EGFR inhibitors in lung cancer

Rule	Reference	Evaluation
I-1	Patient is ≥18 years of age.	PASS Patient is at least 18 years old
I-2	Drug 1 as monotherapy is indicated for the treatment of adults with advanced lung cancer.	PASS Patient has lung cancer Tumor stage IV is considered metastatic
I-3	Patient has a confirmed EGFR C797S mutation	PASS Variant(s) C797S in gene EGFR detected in canonical transcript

METC 04 - Lung cancer C797S cohort

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	Yes
Has slots available?	Yes

Other trials & cohorts

METC 03

Potentially eligible	No
Acronym	NO-SEE797ES
Title	Phase I trial for development of NO-SEE797ES, a specific inhibitor for EGFR with C797 mutations but not C797S in solid tumors

Rule	Reference	Evaluation
I-03	Tumors should contain EGFR C797 but not EGFR C797S mutation.	FAIL Variant(s) C797S in gene EGFR detected in canonical transcript

METC 03 - Dose escalation - monotherapy

Cohort ID	A
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes